Icon saw steady growth of 3.1% for the first quarter as sales just tipped the $400 million mark.

With news reports suggesting Pfizerhas killed off its planned $160 billion megamerger with Allergan after a crackdown from the U.S. Treasury, CROs may have a…

Covance has helped buoy LabCorp earnings in the fourth quarter as its leadership team hails a "transformative year."

Icon has seen strong growth in the fourth quarter as new acquisitions and partnerships helped shore up growth.

Catalent Pharma Solutions remained stagnant in its fiscal second quarter, as global currency fluctuations undid baseline growth in its banner businesses.…

Quintiles, the world's larget CRO, is expecting its revenue to jump as much as 8.5% in 2016 on the heels of a record year.

Parexel lowered its fiscal year revenue projections by about 2% despite posting modest growth in the last quarter, working through a sizable restructuring…

German contract researcher Evotec grew its revenue by 50% in the first 9 months of 2015, executing its hybrid model and expanding its list of Big Pharma…